Division of Hematology and Oncology

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

Mary Philip, MD, PhD, left, and Michael Rudloff, PhD, found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. (photo by Anthony Czelusniak)

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

New treatment option for metastatic colorectal cancer prolongs survival

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

Liquid biopsy test may detect early-stage and low DNA-shedding cancers

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.

Lovly elected to American Association for Cancer Research board

Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.

1 2 3 4 5 15